Bioray’s BR-111 cleared to enter clinic in China for ROR1-positive cancers
Feb. 10, 2025
Bioray Pharmaceutical Co. Ltd. has announced clinical trial clearance in China by the National Medical Products Administration (NMPA) for BR-111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.